Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...
Study data presented at ACTRIMS 2026 suggests clinical MS onset may precede laboratory-confirmed primary EBV infection in some patients.
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results